oseen · source-linked reporting

A study published by The New England Journal of Medicine reports that the daraxonrasib, a RAS inhibitor drug

Sudanese cholera epidemic — A study published by The New England Journal of Medicine reports that the daraxonrasib, a RAS inhibitor drug that targets KRAS-mutated cancers, has doubled median overall survival

Published May 31, 2026· Updated October 28, 2026·1 min read

Context: Sudanese cholera epidemic.

A study published by The New England Journal of Medicine reports that the daraxonrasib, a RAS inhibitor drug that targets KRAS-mutated cancers, has doubled median overall survival in patients with metastatic pancreatic cancer as compared to chemotherapy. [https://www.npr.org/2026/05/31/nx-s1-5841859/experimental-pill-new-hope-pancreatic-cancer (NPR)] [https://www.reuters.com/business/healthcare-pharmaceuticals/revolutions-pancreatic-cancer-drug-doubles-survival-boosts-quality-life-2026-05-31/ (Reuters)] [https://www.nejm.org/doi/full/10.1056/NEJMoa2605555 (NEJM)]

Event summary via Wikipedia Current Events (2026-05-31).